Fluoropyrimidine-HAI (hepatic arterial infusion) versus systemic chemotherapy (SCT) for unresectable liver metastases from colorectal cancer

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2009, Pages

  Mocellin, Simone ^a   Pasquali, Sandro ^a   Nitti, Donato ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b Policlinico Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FLOXURIDINE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; HEPARIN;

CANCER CHEMOTHERAPY; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; HUMAN; INTERMETHOD COMPARISON; LIVER METASTASIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

EID: 70049098745     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007823.pub2     Document Type: Review

References (36)

1. Allen-Mersh TG, Earlam S, Fordy C, Abrams K, Houghton J. Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal livermetastases. Lancet 1994;344(8932):1255-1260 [PUBMED: 7526096] (Pubitemid 24334681)
2. Chang AE, Schneider PD, Sugarbaker PH, Simpson C, Culnane M, Steinberg SM. A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Annals of surgery 1987;206(6):685-693 [PUBMED: 2961314] (Pubitemid 18056182)
3. Hohn DC, Stagg RJ, Friedman MA, Hannigan JF Jr, Rayner A, Ignoffo RJ, et al. A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(11):1646-1654 [PUBMED: 2530317] (Pubitemid 19272834)
4. * Kemeny N, Daly J, Reichman B, Geller N, Botet J, Oderman P. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Annals of internal medicine 1987;107(4):459-465 [PUBMED: 2957943]
5. Kemeny NE, Niedzwiecki D, Hollis DR, Lenz HJ, Warren RS, Naughton MJ, et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(9):1395-1403 [PUBMED: 16505413] (Pubitemid 46622004)
6. Kerr DJ, McArdle CS, Ledermann J, Taylor I, Sherlock DJ, Schlag PM, et al. Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial. Lancet 2003;361(9355):368-373 [PUBMED: 12573372] (Pubitemid 36164968)
7. Lorenz M, Muller HH. Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2000;18(2):243-254 [PUBMED: 10637236] (Pubitemid 30056411)
8. Martin JK Jr, O'Connell MJ, Wieand HS, Fitzgibbons RJ Jr, Mailliard JA, Rubin J, et al. Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. Archives of surgery (Chicago, Ill. : 1960) 1990;125(8):1022-1027 [PUBMED: 2143063] (Pubitemid 20249340)
9. Rougier P, Laplanche A, Huguier M, Hay JM, Ollivier JM, Escat J, et al. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(7):1112-1118 [PUBMED: 1296590]
10. Wagman LD, Kemeny MM, Leong L, Terz JJ, Hill LR, Beatty JD, et al. A prospective, randomized evaluation of the treatment of colorectal cancer metastatic to the liver. Journal of clinical oncology : official journal of the American Society ofClinicalOncology 1990;8(11):1885-1893 [PUBMED: 2146370] (Pubitemid 20382353)
11. Alberts SR, Wagman LD. Chemotherapy for colorectal cancer liver metastases. The oncologist 2008;13(10):1063-1073 [PUBMED: 18838438]
12. Alderson P, Green S, Higgins JPT. Wiley, New York, NY. Reviewers' Handbook 4.2.2, 2004.
13. Allen PJ, Nissan A, Picon AI, Kemeny N, Dudrick P, Ben-Porat L, et al. Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: an institutional experience of 544 consecutive cases. Journal of the American College of Surgeons 2005;201(1):57-65. [PUBMED: 15978444] (Pubitemid 40840564)
14. Boige V, Malka D, Elias D, Castaing M, De Baere T, Goere D, et al. Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure. Annals of surgical oncology 2008;15(1):219-226 [PUBMED: 17896145]
15. Carnaghi C, Santoro A, Rimassa L, Doci R, Rosati R, Pedicini V, et al. The efficacy of hybrid chemotherapy with intravenous oxaliplatin and folinic acid and intra-hepatic infusion of 5-fluorouracil in patients with colorectal liver metastases: a phase II study. Investigational new drugs 2007;25(5):479-485 [PUBMED: 17492399] (Pubitemid 47222907)
16. Curran D, Sylvester RJ, Hoctin Boes G. Sample size estimation in phase III cancer clinical trials. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 1999;25(3):244-250 [PUBMED: 10336801] (Pubitemid 29261282)
17. Dizon DS, Schwartz J, Kemeny N. Regional chemotherapy: a focus on hepatic artery infusion for colorectal cancer liver metastases. Surgical oncology clinics of North America 2008;17(4):759-71, viii. [PUBMED: 18722916]
18. Dupont WD, Plummer WD Jr. Power and sample size calculations. A review and computer program. Controlled clinical trials 1990;11(2):116-128 [PUBMED: 2161310]
19. Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000;56(2):455-463 [PUBMED: 10877304] (Pubitemid 30422636)
20. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical research ed.) 1997;315(7109):629-634 [PUBMED: 9310563] (Pubitemid 27387172)
21. Gallagher DJ, CapanuM, Raggio G, Kemeny N. Hepatic arterial infusion plus systemic irinotecan in patients with unresectable hepatic metastases from colorectal cancer previously treated with systemic oxaliplatin: a retrospective analysis. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(12):1995-1999 [PUBMED: 17962209] (Pubitemid 350286238)
22. Ganeshan A, Upponi S, Hon LQ, Warakaulle D, Uberoi R. Hepatic arterial infusion of chemotherapy: the role of diagnostic and interventional radiology. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(5):847-851 [PUBMED: 18029972] (Pubitemid 351627299)
23. Harmantas A, Rotstein LE, Langer B. Regional versus systemic chemotherapy in the treatment of colorectal carcinoma metastatic to the liver. Is there a survival difference? Meta-analysis of the published literature. Cancer 1996;78(8):1639-1645 [PUBMED: 8859174] (Pubitemid 26330889)
24. Homsi J, Garrett CR. Hepatic arterial infusion of chemotherapy for hepatic metastases from colorectal cancer. Cancer control : journal of the Moffitt Cancer Center 2006;13(1):42-47 [PUBMED: 16508625] (Pubitemid 43327553)
25. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA: a cancer journal for clinicians 2008;58(2):71-96. [PUBMED: 18287387]
26. Meta-Analysis Group in Cancer. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. Meta-Analysis Group in Cancer. Journal of the National Cancer Institute 1996;88(5):252-258 [PUBMED: 8614003]
27. Kemeny N, Fata F. Hepatic-arterial chemotherapy. Lancet Oncology 2001;2(7):418-428 [PUBMED: 11905736]
28. Lise M, Mocellin S, Pilati P, Nitti D. Colorectal liver metastasis: towards the integration of conventional and molecularly targeted therapeutic approaches. Frontiers in Bioscience 2005;10:3042-3057 [PUBMED: 15970559] (Pubitemid 40910543)
29. Mocellin S, Hoon D, Ambrosi A, Nitti D, Rossi CR. The prognostic value of circulating tumor cells in patients with melanoma: a systematic review and meta-analysis. Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(15):4605-4613 [PUBMED: 16899608] (Pubitemid 44297811)
30. Neyns B, Aerts M, Van Nieuwenhove Y, Fontaine C, De Coster L, Schallier D, et al. Cetuximab with hepatic arterial infusion of chemotherapy for the treatment of colorectal cancer liver metastases. Anticancer research 2008;28(4C):2459-2467 [PUBMED: 18751435]
31. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in medicine 1998;17(24):2815-2834 [PUBMED: 9921604] (Pubitemid 28562978)
32. Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F. John Wiley & Sons Ltd. New York.. Methods for meta-analysis in medical research, 2000.
33. Thompson SG, Sharp SJ. Explaining heterogeneity in meta-analysis: a comparison of methods. Statistics in medicine 1999;18(20):2693-2708 [PUBMED: 10521860]
34. Weitz J, Koch M, Debus J, Hohler T, Galle PR, Buchler MW. Colorectal cancer. Lancet 2005;365(9454):153-165 [PUBMED: 15639298]
35. White RR, Jarnagin WR. The role of aggressive regional therapy for colorectal liver metastases. Cancer investigation 2007;25(6):458-463 [PUBMED: 17882658]
36. Wolpin BM, Mayer RJ. Systemic treatment of colorectal cancer. Gastroenterology 2008;134(5):1296-1310 [PUBMED: 18471507]